Subject: Unimed Is Licensing Marinol To Korea's Keun Wha
Date: Published: 11/4/91 (34 lines)
Source:  Wall Street Journal.  Copyright Dow Jones & Co. Inc. 

    Unimed Is Licensing
    Its Anti-Nausea Drug
    To Korea's Keun Wha

    SOMERVILLE, N. J. -- Unimed Inc. said it signed a licensing
 and supply agreement with Keun Wha Pharmaceutical Co. of
 Seoul, South Korea, for Unimed's Marinol anti-nausea drug for
 cancer chemotherapy patients.  Terms weren't disclosed.
    Under the agreement, Keun Wha will finance certain
 clinical work and obtain product registration for Marinol in
 South Korea.  It also will pay Unimed a licensing fee at
 registration.  It said it expects Keun Wha to file the product
 registration in a few months, with approval expected between
 one and two years after that.
    Harold J. Tenoso, Unimed's chairman, said in a statement
 that the agreement is the company's first Asian alliance for
 Marinol, its brand of dronabinol.  Charles Harrison, Unimed
 president, said that the drug is approved and currently being
 used in the U. S., Canada and Israel, and that the company has
 alliances in Spain and Portugal with companies seeking
 approval in those markets.
    Unimed noted that Marinol is undergoing U. S. clinical
 trials for appetite stimulation and weight-loss prevention in
 AIDS patients.  It added that the Food and Drug Administration
 has granted Marinol orphan-drug status for those uses when
 marketing approval is granted.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]